B
BioNTech
Develops personalized immunotherapies with a focus on cancer medicine
At a glance
- Status
- Listed
- Listing
- IPO 2019
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
1k+ Global Genetics & Genomics startups
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in Germany
Analysis
Moderna vs BioNTech
Sep 11, 2026
Analysis
Europe's Decacorns & Centicorns — the Map
Aug 23, 2026
Open roles
BioNTech in the Mainz ecosystem
The BioNTech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- AVATHOS Venture
- MCMIG Capital
- SHSanto Holding
Series A6 investors entered at this stage
- INInvus
- RGRedmile Group
Janus Henderson Investors
- ELEli Lilly
- JHJanus Henderson
Fidelity Investments
Series B and later8 investors entered at this stage
- PMPlatinum Asset Management
- JMJohannes Gutenberg University Mainz
- JCJebsen Capital
- MIMirae Asset Venture Investment
Temasek- SASanofi
- GEGenentech
- BABayer
Source: Dealroom Talent Intelligence.
Patents
583 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where BioNTech was the backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
13 deals across BioNTech's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where BioNTech deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
BioNTech's portfolio, mapped.
See BioNTech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
BioNTech and DualityBio report modest Phase 3 win for trastuzumab pamirtecan in HR+/HER2-low breast cancer
BioNTech's BNT113 misses PFS endpoint in Phase 2/3 head and neck cancer trial
BioNTech and OncoC4 report gotistobart nearly doubles median overall survival in squamous lung cancer Phase 3